ABOUT US

Unizima is catalyzing the geographically diversified manufacturing of biologics

ABOUT US

Unizima is catalyzing the
geographically diversified manufacturing
of biologics

RE-IMAGINING ACCESS TO BIOLOGICS

The gap between scientific innovation and access to medicines has continued to grow

Global supply chains for the manufacturing and distribution of vital biologics are broken. The fault lines in access to biologics, particularly in the Global South, were amplified by the Covid-19 pandemic. There is growing consensus that the collective vision of a more equitable and resilient world is unattainable without a new approach to biomanufacturing.

shutterstock_2015750855

We enable and promote affordable, custom-designed and sustainable manufacturing solutions

lab-tubes-2

PROVIDING END-TO-END SOLUTIONS FOR YOUR
BIOMANUFACTURING NEEDS

Unizima is a biomanufacturing services and technology provider, providing the expertise and technology needed to enable sustainable production of biologics such as vaccines, monoclonal antibodies and insulin in new regions.

We serve as a trusted partner for biopharma manufacturers, governments and global health agencies to make biologics production in low- and middle-income countries (LMICs) and emerging markets a reality.

We are driven by the end goal of delivering life-changing biologics to people who would otherwise lack access to them. We are part of the Univercells Group and share its ground-breaking technology and engineering innovations.

Biologics beyond borders

HOW CAN WE WORK TOGETHER?

advise-team-meeting

Advise

Unizima provides objective, strategic and technical advice to governments, multilateral institutions, manufacturers and funders covering the technical, financial and regulatory aspects of their biomanufacturing projects.

Design & Build

We deliver turnkey services for local partners to set up new, state of-the art biomanufacturing facilities, or to upgrade capacity in existing facilities across the value chain, including R&D, drug substance and drug product sites.

design-build-img
collaborate-1055627844

Collaborate

We forge partnerships between public and private sector organisations including funders, global health agencies and biotech organizations to catalyse breakthrough approaches to biomanufacturing in LMICs and emerging markets.

WHY PARTNER WITH US?

Unizima can add value to your projects in three distinct ways

Unizima Homepage Rapid Turnaround

Rapid Turnaround

We provide a full suite of services that includes strategy, product licensing, design and build of facilities and workforce development all in one place. This allows customers to accelerate the implementation and operations of their facility, delivering locally produced biologics.

Homepage Icons Bioreactor

Technology-driven Affordability

We offer access to the next generation of bioproduction technologies and know how of the Univercells Group enabling low-cost and low-footprint production. The same principles of value engineering that created these ground-breaking technologies are applied to every project, to make them as economical and technologically innovative as possible.

Unizima Homepage Expertise Grounded in Reality

Expertise Grounded in Reality

Our team has extensive global experience in manufacturing strategy, investment profitability analysis, engineering, biologics manufacturing, GMP and Quality Assurance, Regulatory Affairs, supply chain, logistics management and recruitment. Our solutions are designed by leveraging local expertise and networks to overcome the unique challenges to delivering complex projects in each region.

FEATURED PROJECTS

unizima-africa-senegal-green
Senegal

Working with Institut Pasteur de Dakar, Unizima is providing recruitment, workforce development and operational support for the Manufacturing in Africa for Disease Immunisation and Building Autonomy (MADIBA) project, a first-of-its kind, modular African CDMO for vaccines. Funded by a coalition of international donors and governments, MADIBA will leverage Unizima’s expertise and Univercells’ equipment, to reach a capacity of 300 million doses/year for a range of epidemic and routine diseases.

unizima-africa
Africa

Unizima was selected by the Deutsche Gesellschaft für Internationale Zusammenarbeit (GIZ) GmbH to conduct a business case simulation for fill & finish contract manufacturing operations in Africa to cover the demand for routine and novel vaccines.

unizima-middle-east-saudi
Saudi Arabia

Unizima partnered with a global strategy consulting firm to provide technical advice on the life sciences manufacturing strategy for a Saudi Arabia-based client, including reviewing target technologies and testing key recommendations.

unizima-america-and-africa-latin-america-yellow
Latin America and Africa

Unizima has signed an MoU with Servare Biologics to develop more affordable monoclonal antibodies (mAbs) and to increase biomanufacturing skills and capabilities in these regions by implementing training related to tech transfer for drug development and manufacturing.

unizima-africa-eygpt
Egypt

Unizima is working with an established pharma company in Egypt that is willing to empower Fill & Finish capability in its portfolio for insulin and biosimilars. Our team is delivering a diagnosis, a gap analysis, and a design review of modular facility for potential installations.